CELUW vs NBIX · rev $54.2M vs P/E 45, rev $1.77B
Celularity Inc (CELUW) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Celularity Inc (CELUW) common stock listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported CELUW revenue for 2024-12-31 was $54.2M. Net income was -$57.9M. Revenue was up 138.1% from 2023-12-31 to 2024-12-31. CELUW currently screens at market cap $0.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
CELUW currently screens at market cap $0. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the CELUW and NBIX stock pages for the full models.
Not investment advice.